Skip to main content
Clinical Trials/NL-OMON50825
NL-OMON50825
Completed
N/A

Early clinical feasibility study of a new voice prosthesis: the Provox Vega HP - Vega HP study

Atos Medical AB0 sites20 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Atos Medical AB
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Laryngectomized patients using either the Provox Vega 22\.5 or the Provox
  • ActiValve Light voice prosthesis, with a length of 4, 6, 8, or 10 mm
  • 18 years and older

Exclusion Criteria

  • Current tracheoesophageal puncture problems such as enlarged puncture or
  • Active recurrent or metastatic disease (medical deterioration)
  • The use of ActiValve Strong/XtraStrong or XtraSeal
  • Unable to understand the Patient Information and/or unable to give Informed

Outcomes

Primary Outcomes

Not specified

Similar Trials